Products for Research Use Only

Lorigerlimab

CAT: 0804-HY-P99714-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P99714-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART) . Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) [1][2][3].
CAS Number
2416595-46-3
Product Name Alternative
MGD019
UNSPSC
12352203
Target
CTLA-4; PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lorigerlimab.html
Purity
97.5
Solubility
10 mM in DMSO
Smiles
[Lorigerlimab]
Molecular Weight
(166.4 kDa)
References & Citations
[1]Jason J. Luke, et al. Lorigerlimab, a bispecific PD-1xCTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) : A phase 1 expansion (exp) cohort. Journal of Clinical Oncology 2023 41:6_suppl, 155-155. |[2]Berezhnoy A, et al. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1 (9) :100163. |[3]Trojaniello C, Luke JJ, Ascierto PA. Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. Front Oncol. 2021 Jun 10;11:670726.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2

Popular Products